Chronic Obstructive Pulmonary Disease (COPD) is a severe respiratory condition affecting the lungs. It is commonly associated with chronic bronchitis, a condition characterized by inflammation and narrowing of the airways, leading to excessive mucus production and a persistent cough. People with this condition often experience persistent coughing, shortness of breath, and increased mucus production. COPD with bronchitis is usually caused by smoking or exposure to harmful pollutants. It's a progressive disease that worsens over time, leading to reduced lung function and decreased quality of life. Quitting smoking, avoiding irritants, and following a doctor's treatment plan can help manage COPD with bronchitis.
In the search for effective treatment options, N-acetylcysteine (NAC) has been considered a potential therapeutic choice for COPD patients with chronic bronchitis. NAC is an antioxidant and mucolytic agent that helps break down mucus, making it easier to clear the airways. It is commonly used to manage chronic bronchitis symptoms and to improve lung function.
Clinical Trial
A randomized, double-blind, placebo-controlled trial was conducted to assess the clinical efficacy of high-dose oral NAC for COPD patients with concurrent chronic bronchitis. The study enrolled 143 participants initially, but only 100 patients were ultimately included in the research. These patients were randomly assigned to receive either 900 mg of NAC twice daily or a matching placebo for three months.The study's primary endpoint was the evaluation of respiratory health status using the St. George's Respiratory Questionnaire (SGQR). The SGQR is a validated tool that assesses various aspects of respiratory health and quality of life, including symptoms, activity limitations, and social and psychological well-being impacts.